Clinical trial · Observational
Effectiveness of Managing Suspected Metastasis and Progress Using Plasma D-dimer Testing in Gastric Cancer Patients
NCT04953585CI-TRIAL-00052607EMPUPDTGCPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For prognosis evaluation, investigators enroll gastric cancer patients who underwent radical gastrectomy and collect the laboratory examination and clinicopathological characteristics. Then independent risk factors for overall survival will be analysed. For predicting efficacy evaluation, investigators also collect information of patients first diagnosed with metastases. Diagnostic efficacy is analysed by receiver operator characteristic curve method.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radical gastrectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Normal D-dimer group
- description
- preoperative plasma D-dimer levels less than or equal to 1mg/L
- interventionNames
- Procedure: radical gastrectomy
- label
- Elevated D-dimer group
- description
- preoperative plasma D-dimer levels greater than 1mg/L
- interventionNames
- Procedure: radical gastrectomy
Primary outcomes (1)
- measure
- overall survival time
- timeFrame
- From date of radical gastrectomy until the date of last follow-up or date of death from gastric cancer, whichever came first, assessed up to 48 months
- description
- From date of radical gastrectomy until the date of last follow-up or date of death from gastric cancer, whichever came first, assessed up to 48 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * all patients were newly diagnosed with gastric cancer; * all patients were pathologically diagnosed; * all patients had pre-treatment coagulation test; * stage I-IV disease; * age≥18 years Exclusion Criteria: * accompanying or secondary to other tumors; * had history of venous thrombosis or received any anti-coagulation treatment; * acute infection or intravascular disseminated coagulation; * pregnancy or lactation; * history of neoadjuvant chemotherapy; * Lost to follow-up
References
Publications (0)
Data not yet available
No reference posted for this study.